- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00003984
Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome
Phase II Trial With a Recombinant Humanized Anti-CD33 Monoclonal Antibody (HuM195) in Patients With High Risk Primary Myelodysplastic Syndromes
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have primary myelodysplastic syndrome.
Panoramica dello studio
Descrizione dettagliata
OBJECTIVES: I. Assess the therapeutic activity of monoclonal antibody HuG1-M195 on peripheral blood and bone marrow blast cell count, blood leukocyte, reticulocyte, and platelet counts, and hemoglobin levels in patients with myelodysplastic syndrome with refractory anemia with excess blasts (RAEB) (greater than 10% bone marrow myeloblasts) or RAEB in transformation. II. Assess the efficacy of this drug in terms of duration of response in these patients. III. Evaluate the toxicity of this drug in these patients.
OUTLINE: Patients receive monoclonal antibody HuG1-M195 IV over 4 hours on days 1-4. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with progressive disease after 2 courses are removed from study. Patients with stable disease receive no further treatment after 4 courses. Patients with complete or partial response receive treatment for 4 additional courses. Patients are followed at 11 and 39 days after end of course 4, monthly for 4 months, then every 3 months thereafter for 1 year from study entry.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Tipo di studio
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Innsbruck, Austria, A-6020
- Innsbruck Universitaetsklinik
-
Vienna, Austria, A-1100
- Kaiser Franz Josef Hospital
-
-
-
-
-
Brussels, Belgio, 1000
- Institut Jules Bordet
-
Brussels, Belgio, B-1200
- Ludwig Institute for Cancer Research-Brussels Branch
-
Edegem, Belgio, B-2650
- Universitair Ziekenhuis Antwerpen
-
Leuven, Belgio, B-3000
- U.Z. Gasthuisberg
-
-
-
-
-
Herlev, Danimarca, DK-2730
- Herlev Hospital - University Hospital of Copenhagen
-
-
-
-
-
Clermont-Ferrand, Francia, 63011
- Centre Jean Perrin
-
Lyon, Francia, 69373
- Centre Léon Bérard
-
Nantes-Saint Herblain, Francia, 44805
- CRLCC Nantes - Atlantique
-
Toulouse, Francia, 31052
- Institut Claudius Regaud
-
Villejuif, Francia, F-94805
- Institut Gustave Roussy
-
-
-
-
-
Essen, Germania, D-45122
- Universitaetsklinik und Strahlenklinik - Essen
-
Nuremberg (Nurnberg), Germania, D-90419
- Klinikum Nürnberg
-
-
-
-
-
Oslo, Norvegia, N-0310
- Norwegian Radium Hospital
-
-
-
-
-
Amsterdam, Olanda, 1066 CX
- Antoni van Leeuwenhoekhuis
-
Amsterdam, Olanda, 1117 MB
- Academisch Ziekenhuis der Vrije Universiteit
-
Groningen, Olanda, 9713 EZ
- Academisch Ziekenhuis Groningen
-
Nijmegen, Olanda, NL-6252 HB
- University Medical Center Nijmegen
-
Rotterdam, Olanda, 3075 EA
- Rotterdam Cancer Institute
-
-
-
-
England
-
Newcastle Upon Tyne, England, Regno Unito, NE4 6BE
- Newcastle General Hospital
-
-
Scotland
-
Dundee, Scotland, Regno Unito, DD1 9SY
- Ninewells Hospital and Medical School
-
Edinburgh, Scotland, Regno Unito, EH4 9NQ
- Western General Hospital
-
Glasgow, Scotland, Regno Unito, G61 1BD
- C.R.C. Beatson Laboratories
-
-
-
-
-
Basel, Svizzera, CH-4031
- University Hospital
-
Bern, Svizzera, CH-3010
- Inselspital, Bern
-
Saint Gallen, Svizzera, CH-9007
- Kantonsspital - Saint Gallen
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
DISEASE CHARACTERISTICS: Histologically confirmed primary myelodysplastic syndrome (MDS) with greater than 10% bone marrow blasts Refractory anemia with excess blasts (RAEB) OR RAEB in transformation No chronic myelomonocytic leukemia No secondary MDS after prior chemotherapy except if treatment was for acute myeloid leukemia No allogeneic bone marrow transplantation planned
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: At least 3 months Hematopoietic: Hemoglobin no greater than 10 g/dL OR transfusion requirement of at least 3 packs of RBCs per month OR Platelet count less than 50,000/mm3 OR Absolute neutrophil count less than 1,000/mm3 No disseminated intravascular coagulation defined as fibrinogen less than 100 mg/dL AND prolonged PT, PTT, or thrombin time AND platelet count less than 25,000/mm3 without transfusion Hepatic: Bilirubin no greater than 2.0 mg/dL Alkaline phosphatase no greater than 4 times upper limit of normal (ULN) (unless due to underlying disease or Gilbert's syndrome) SGPT and SGOT no greater than 4 times ULN (unless due to underlying disease or Gilbert's syndrome) Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No uncontrolled hypertension No congestive heart failure, cardiac arrhythmia, or angina pectoris No history of myocardial infarction within the past 6 months No other significant cardiovascular disease LVEF within normal range by MUGA or echocardiogram No active ischemia Pulmonary: No pulmonary dysfunction Other: No central or peripheral neuropathy No uncontrolled or unstable diabetes No other significant organ system dysfunction HIV negative No prior malignancy except basal cell carcinoma or carcinoma in situ of the uterus No active, uncontrolled infection Not pregnant or nursing Fertile patients must use effective contraception during and for 3 months after study
PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 2 months since prior biologic therapy (e.g., hematopoietic growth factors or biological response modifiers) Chemotherapy: See Disease Characteristics At least 2 months since prior chemotherapy Endocrine therapy: At least 2 months since prior endocrine therapy Radiotherapy: At least 2 months since prior radiotherapy Concurrent radiotherapy allowed Surgery: At least 2 months since prior surgery Other: No other concurrent investigational drugs
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
Collaboratori e investigatori
Investigatori
- Cattedra di studio: Heinz Zwierzina, MD, Medical University Innsbruck
Studiare le date dei record
Studia le date principali
Inizio studio
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- EORTC-13981
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su lintuzumab
-
Actinium PharmaceuticalsTerminatoMieloma multiplo refrattarioStati Uniti
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Sconosciuto
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletatoSindromi mielodisplastiche | LeucemiaStati Uniti
-
Seagen Inc.CompletatoLeucemia mieloide acuta | Malattie mieloproliferative | Leucemia Mielomonocitica Cronica | Sindrome mielodisplasicaStati Uniti
-
Medical College of WisconsinAttivo, non reclutante
-
Joseph JurcicRitiratoLeucemia mieloide acuta
-
Alison WalkerSeagen Inc.TerminatoSindromi mielodisplastiche | LeucemiaStati Uniti
-
Actinium PharmaceuticalsRitiratoLeucemia mieloide acuta | LMA adulta recidivante
-
Seagen Inc.CompletatoSindrome mielodisplastica (MDS)Stati Uniti
-
M.D. Anderson Cancer CenterCompletatoLeucemia mieloide acuta | Malattie mieloproliferative | Leucemia Mielomonocitica Cronica | Anemia, refrattaria, con eccesso di blastiStati Uniti